RT Journal Article SR Electronic T1 ▼ Safinamide for Parkinson’s disease JF Drug and Therapeutics Bulletin JO Drug Ther Bull FD BMJ Publishing Group Ltd SP 54 OP 57 DO 10.1136/dtb.2018.5.0623 VO 56 IS 5 YR 2018 UL http://dtb.bmj.com/content/56/5/54.abstract AB ▼ Safinamide (Xadago - Zambon S.p.A) is a monoamine-oxidase B (MAO-B) inhibitor licensed as add-on therapy for people with idiopathic Parkinson’s disease who are experiencing motor fluctuations with levodopa.1 Currently there is no cure for Parkinson’s disease and drugs are used to reduce motor symptoms and improve daily activities.2,3 Here, we review the evidence for this MAO-B inhibitor.